禾元生物：全国各省份已陆续销售奥福民

Core Viewpoint - He Yuan Bio has successfully completed the listing of its drug, Aofumin (recombinant human albumin injection), in the procurement catalog across various provinces in China, and sales have commenced nationwide [1] Group 1 - The company has responded to investor inquiries regarding the sales status of Aofumin, indicating that it is now available in multiple provinces [1] - Aofumin's sales performance will be detailed in the upcoming annual report, scheduled for release on April 28, 2026, covering the fiscal year 2025 [1]